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Edited by David LambethAbstract Serum levels of advanced glycation end products
(AGEs) are associated with an acute phase reactant, C-reactive
proteins (CRP) in diabetic patients. However, whether AGEs
could directly stimulate hepatic CRP production remains to be
elucidated. We found here that AGEs upregulated CRP mRNA
levels in cultured Hep3B cells via Rac-1 activation, which was
blocked by pigment epithelium-derived factor (PEDF). Our pres-
ent study suggests that AGEs are one of the potent inducers of
CRP and that PEDF may work as an anti-inﬂammatory agent
against AGEs in the liver.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PEDF1. Introduction
C-reactive protein (CRP) is an acute phase reactant mainly
produced by liver in response to pro-inﬂammatory cytokines
such as interlekin-6 (IL-6) [1,2]. There is a growing body of evi-
dence to show that CRP is one of the most powerful predictors
of future cardiovascular events [3,4]. In addition, CRP has
been shown to elicit endothelial cell activation, pro-inﬂamma-
tory reactions and smooth muscle cell proliferation, thus
participating in the development and progression of athero-
sclerosis as well [5–7].
Non-enzymatic modiﬁcation of proteins by reducing sugars,
a process that is also known as Maillard reaction, progress at
an extremely accelerated rate under diabetes, leading to the
formation of advanced glycation end products (AGEs)
in vivo [8,9]. Recent understandings of this process have re-
vealed that AGEs and their receptor RAGE interaction plays
a central role in the pathogenesis of diabetic vascular compli-
cations [8–16]. Indeed, there is a growing body of evidence thatAbbreviations: CRP, C-reactive protein; IL-6, interlekin-6; AGEs,
advanced glycation end products; RAGE, receptor for AGEs; ROS,
reactive oxygen species; PEDF, pigment epithelium-derived factor;
BSA, bovine serum albumin; DPI, diphenylene iodonium; NAC, N-
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engagement of RAGE by AGEs evokes inﬂammatory re-
sponses in vascular wall cells [14–16]. Serum levels of AGEs
are one of the biomarkers of coronary heart disease in type 2
diabetic patients [17]. Moreover, serum concentration of
AGEs is also found to be an independent determinant of ser-
um levels of CRP in patients with diabetes [18]. Given the ath-
erogenic property of CRP described above, AGEs may
promote atherosclerosis in diabetic patients by acting not only
on vascular wall cells directly, but also on liver to stimulate
CRP proteins. Hepatic AGE binding is actually increased in
experimental diabetes [19], further suggesting the direct patho-
logical eﬀects of AGEs on the liver. However, whether AGEs
could be one of the potent inducers of CRP proteins by the li-
ver remains to be elucidated.
AGEs exert pleiotropic actions on various types of cells by
inducing the generation of intracellular reactive oxygen species
(ROS) [14–16]. Furthermore, we have recently found that pig-
ment epithelium-derived factor (PEDF), a glycoprotein that
belongs to the superfamily of serine protease inhibitors with
potent neuronal diﬀerentiating activity, blocks the AGE-in-
duced vascular cell injury by suppressing ROS generation
in vitro [20,21]. Therefore, in this study, we ﬁrst examined
whether and how AGEs could stimulate CRP expression in
cultured human hepatoma cells. Then we further examined
whether PEDF could block the AGE-signaling to CRP expres-
sion in the hepatoma cells and the way that it might achieve
this eﬀect.2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA) (fraction V), diphenylene iodonium
(DPI), an inhibitor of NADPH oxidase, N-acetylcysteine (NAC), ebse-
len, HEPES, EDTA, dithiothreitol (DTT), orthovanadate, NP-40, or
glycerol were purchased from Sigma (St. Louis, MO, USA). Antiserum
against human RAGE for neutralizing assays, which recognizes the
amino acid residues 167–180 of human RAGE protein, was prepared
as described previously [22]. Protease inhibitor cocktails were from
Nakalai Tesque (Kyoto, Japan). Antibodies (Abs) against phsophory-
lated (Ser 727)-STAT3, phsophorylated (Tyr 705)-STAT3 were pur-
chased from Cell Signaling (Beverly, MA, USA). Abs against
STAT3 and Rac-1 was purchased from Santa Cruz Biotechnology
(Delaware, CA, USA) and Cytoskelton, Inc (Acoma street, Denver,
USA), respectively.blished by Elsevier B.V. All rights reserved.
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AGE–BSA was prepared as described previously [11]. Brieﬂy, BSA
was incubated under sterile conditions with D-glyceraldehyde for 7
days. Then unincorporated sugars were removed by dialysis against
phosphate-buﬀered saline. Control non-glycated BSA was incubated
in the same conditions except for the absence of reducing sugars. Prep-
arations were tested for endotoxin using Endospecy ES-20S system
(Seikagaku Co., Tokyo, Japan); no endotoxin was detectable.
2.3. Puriﬁcations of PEDF proteins
PEDF proteins were puriﬁed as described previously [21]. SDS–
PAGE analysis of puriﬁed PEDF proteins revealed a single band with
a molecular weight of about 50 kDa, which showed positive reactivity
with monoclonal Abs against human PEDF (Transgenic, Kumamoto,
Japan).
2.4. Preparation of polyclonal Abs against human PEDF
Polyclonal Abs against human PEDF were prepared as described
previously [21]. We conﬁrmed that the Abs actually bound to puriﬁed
PEDF proteins.
2.5. Cells
Human hepatoma Hep3B cells were obtained from ATCC (Manas-
sas, VA, USA) and maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% of fetal bovine serum, penicillin (100 U/ml),
and streptomycin (100 U/ml) at 37 C in a humidiﬁed atmosphere
containing 5% CO2.
2.6. Measurement of CRP
CRP levels in the medium where Hep3B cells were grown were mea-
sured with an Assay Max Human C-Reactive Protein ELISA kit (As-
say Pro, Winﬁeld, MO, USA) according to the manufacturer’s
instruction.
2.7. Quantitative real-time reverse transcription-polymerase chain
reaction
Total RNA was extracted with Trizol Reagent (Invitrogen, Carsbad,
CA, USA) according to the manufacturer’s instructions. Real-time
quantitative reverse transcription-polymerase chain reaction (RT-
PCR) was performed using SYBR green reagent (Applied Biosystems,
Foster city, CA, USA) according to the manufacturer’s recommenda-
tion. Primers of CRP and GAPDH were as follows: CRP forward
primer, 5 0-CCCTGAACTTTCAGCCGAATACA-3 0; CRP reverse pri-
mer 5 0-CGTCCTGCTGCCAGTGATACA-3 0, GAPDH forward pri-
mer, 5 0-TGCACCACCAACTGCTTAGC-3 0; GAPDH reverse primer
5 0-GGCATGGACTGTGGTCATGAG-3 0.2.8. Measurement of intracellular ROS generation
Hep3B cells were incubated with 100 lg/ml BSA or the indicated
concentrations of AGE–BSA in the presence or absence of 30 or
100 nM PEDF, 5 lg/ml PEDF Abs, 1 mM NAC, 1 nM ebselen,
10 nM DPI or 0.1% antiserum against RAGE for various time periods.
Then the intracellular formation of ROS was measured using the ﬂuo-
rescent probe CM-H2DCFDA (Molecular Probes, Eugene, OR, USA)
[23].2.9. Transfection of dominant-negative (DN-RacT17N) and constitutive
active (CA-RacG12V) human Rac-1 mutants
Hep3B cells were seed on cell culture dishes (4–5 · 104 cells/cm2) and
then transiently transfected with DN-RacT17N, CA-RacG12V, or an
empty vector using PolyFect Transfection Reagent (Qiagen, GmbH,
Germany) according to the manufacturer’s recommendation.
2.10. Rac-1 pull-down assay and western blotting analysis
Proteins were extracted from Hep3B cells with lysis buﬀer (10 mM
HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT, 1 mM orthovanadate,
1% NP-40, 10% glycerol plus protease inhibitor cocktails), and then
separated by SDS–polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes (Biorad, Hercules, CA, USA) as described
previously [21]. Rac-1 pull-down assay was performed by incubating
cell lysates with GST-PAK PBD protein beads (Cytoskelton, Inc.,Denver, USA) according to the manufacturer’s instructions. Immune
complexes were visualized with an enhanced chemiluminescence detec-
tion system (ECL; Amersham Bioscience, Buckinghamshire, United
Kingdom).
2.11. Measurement of NF-jB p65 activity in nuclear extracts
Nuclear proteins were extracted from the cells with a TransFactor
extraction kit (BD Biosciences Clontech, Palo Alto, CA, USA), and
their binding activities to NF-jB p65 consensus sequence were mea-
sured using a TransFactor NF-jB p65 kit (BD Biosciences Clontech).
2.12. Statistical analysis
All values were presented as means ± S.E. Statistical signiﬁcance was
evaluated using Student’s t test for paired comparison; P < 0.05 was
considered signiﬁcant.3. Results
3.1. Eﬀects of AGEs and PEDF on CRP production by Hep3B
cells
We ﬁrst investigated whether AGEs could stimulate CRP
production by Hep3B cells. As shown in Fig. 1A, AGEs
dose-dependently enhanced the production of CRP proteins
by Hep3B cells; 100 lg/ml AGE–BSA increased the CRP pro-
duction by about 10-fold, compared to 100 lg/ml non-glycated
BSA. Furthermore, PEDF was found to inhibit the AGE-in-
duced increase in CRP production in a dose-dependent man-
ner. We also conﬁrmed that the eﬀects of 100 nM PEDF on
AGE-exposed Hep3B cells were completely reversed by simul-
taneous treatments with 5 lg/ml PEDF-Abs (Fig. 1A).3.2. Eﬀects of AGEs and PEDF on CRP mRNA levels in Hep3B
cells
We next investigated the eﬀects of AGEs and PEDF on CRP
gene expression in Hep3B cells. As the case in CRP protein
production, AGEs were found to time- and dose-dependently
upregulate CRP gene expression in Hep3B cells; the mRNA
levels began to increase at 1 h and up to 6-fold at 24 h after
100 lg/ml AGE treatment, which was signiﬁcantly suppressed
by antiserum against human RAGE (Fig. 1B and C). Further-
more, PEDF, an anti-oxidant, NAC or a glutathione peroxi-
dase mimics, ebselen, or an inhibitor of NADPH oxidase,
DPI, signiﬁcantly suppressed the AGE-induced upregulation
of CRP mRNA levels in Hep3B cells (Fig. 1C). These observa-
tions suggest the possible participation of ROS generation in
the AGE–RAGE-induced CRP gene expression in Hep3B
cells. The PEDF-elicited downregulation of CRP mRNA levels
was also completely reversed by PEDF-Abs (Fig. 1C). We also
conﬁrmed that Hep3B cells expressed RAGE protein (data not
shown).3.3. Eﬀects of AGEs and PEDF on ROS generation in Hep3B
cells
We next examined whether AGEs could actually stimulate
the ROS generation in cultured hepatoma cells. As shown in
Fig. 2A, 100 lg/ml AGE–BSA time-dependently increased
ROS generation as well. However, the time response curve of
ROS production was relatively slowly than that of CRP
mRNA induction. Moreover, there was only a modest increase
in ROS generation; ROS production was signiﬁcantly in-
creased at 6 h and up to 1.3-fold at 24 h, which was suppressed
by antiserum against human RAGE. Further, PEDF, NAC,
Fig. 1. Eﬀects of AGEs or PEDF on CRP expression in Hep3B cells. Hep3B cells were treated with 100 lg/ml BSA or the indicated concentrations of
AGE–BSA in the presence or absence of the indicated concentration of PEDF, 5 lg/ml PEDF-Abs, 1 mM NAC, 1 nM ebselen, 10 nM DPI or 0.1%
antiserum against RAGE. (A) After 48 h, CRP contents in the medium were measured by ELISA. After the indicated time period (B) and 24 h (C)
CRP gene expression was analyzed by quantitative real-time RT-PCR. Data were normalized by the intensity of GAPDHmRNA-derived signals and
related to the value with 100 lg/ml BSA alone ((A) and (C)) or without treatment (B). (A) and (C) *P < 0.05 compared to the value with 100 lg/m
AGE alone. (B) *P < 0.01 compared to the value without treatment. #P < 0.05 compared to the value with 24-h AGE treatment. N > 3. Similar
results were obtained in three independent experiments.
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Fig. 2. Eﬀects of AGEs or PEDF on ROS generation in Hep3B cells. Hep3B cells were treated with 100 lg/ml BSA or the indicated concentrations of
AGE–BSA in the presence or absence of the indicated concentration of PEDF, 5 lg/ml PEDF-Abs, 1 mM NAC, 1 nM ebselen, 10 nM DPI, or 0.1%
antiserum against RAGE for the indicated time period (A) or 24 h (B), and then ROS were quantitatively analyzed. The percentage of ROS
generation is indicated on the ordinate and related to the value without treatment (A) or with 100 lg/ml BSA alone (B). (A) *P < 0.01 compared to
the value without treatment. #P < 0.05 compared to the value with 24-h AGE treatment. (B) *P < 0.05 compared to the value with 100 lg/ml AGE
alone. N > 3. Similar results were obtained in three independent experiments.
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crease in ROS generation (Fig. 2B). These results suggest that
AGE–RAGE interaction elicited the ROS generation in
Hep3B cells via NADPH oxidase activation. Polyclonal Abs
against PEDF reversed the decrease in ROS generation in
100 nM PEDF-exposed Hep3B cells (Fig. 2B).
3.4. Eﬀects of DN-RacT17N or CA-RacG12V on CRP mRNA
levels in Hep3B cells
GTPase Rac-1 is an essential component of NADPH
oxidase [24]. As a pharmacological inhibitor such as DPI is
not absolutely speciﬁc to one cell target, we performed exper-
iments using DN-RacT17N or CA-RacG12V overexpression
techniques to further investigate the involvement of NADPH
oxidase in the AGE-signaling. As shown in Fig. 3A, overex-
pression of DN-RacT17N dose-dependently inhibited the
AGE-induced CRP mRNA upregulation, while CA-RacG12Vtreatment augmented the AGE eﬀects on Hep3B cells. Under
the conditions of CA-RacG12V-overexpression, DPI signiﬁ-
cantly suppressed CRP mRNA levels in AGE-exposed Hep3B
cells (Fig. 3A). These observations suggest that the eﬀect of
Rac-1 on CRP gene expression is mediated, at least in part,
by ROS generation. However, since the CRP mRNA levels
in DPI-treated cells were not decreased to the levels of DN-
RacT17N-treated cells, Rac-1-mediated ROS-independent
pathway could also be involved in the AGE-signaling to
CRP gene induction.
We next examined the involvement of Rac-1 in the AGE-sig-
naling. Rac-1-GTP pull-down assay revealed that active Rac-1
levels began to increase at 1 h and reached a maximum at 3 h
after AGE treatment (Fig. 3B). PEDF was found to signiﬁ-
cantly decrease the levels of active Rac-1 in AGE-exposed
Hep3B cells (Fig. 3C). These observations suggest that Rac-
1, one of the important components of NADPH oxidase, is
Fig. 3. (A) Eﬀects of DN-RacT17N or CA-RacG12V on CRP gene expression. (B) and (C) Eﬀects of AGEs or PEDF on Rac-1 activation. (A)
Hep3B cells were transfected with empty vector (control) or the indicated amounts of DN-RacT17N or CA-RacG12V, and then treated with 100 lg/
ml AGE–BSA in the presence or absence of 10 nM DPI for 24 h. CRP gene expression was analyzed by quantitative real-time RT-PCR. Relative
gene expression level of CRP was shown. *P < 0.05 compared to the value with empty vector. #P < 0.05 compared to the value with 3.0 lg CA-
RacG12V-treated cells. Hep3B cells were treated with 100 lg/ml AGE–BSA or BSA in the presence or absence of 100 nM PEDF for the indicated
time period (B) or 1 h (C). Then, Rac-1 pull-down assay was performed. (B) *P < 0.05 compared to the value without treatment. (C) *P < 0.05
compared to the value with 100 lg/ml BSA alone. N = 3, Similar results were obtained in three independent experiments.
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3.5. Eﬀects of AGEs and PEDF on phosphorylation of STAT3
on both tyrosine (Tyr-705) and serine (Ser-727) residues in
Hep3B cells
STAT3 has been shown to participate in transcriptional acti-
vation of CRP gene by IL-6 [25]. In addition, phosphorylation
of STAT3 on both tyrosine (Tyr-705) and serine (Ser-727) res-
idues is required for maximal transcriptional activity [26].
Therefore, we investigated the involvement of STAT3 phos-
phorylation on both residues on the AGE-signaling to CRPexpression. As shown in Fig. 4A, 100 lg/ml AGEs rapidly in-
duced the phosphorylation of STAT3 on Tyr-705 and Ser-727
residues in Hep3B cells, which was blocked by 100 nM PEDF.
We next examined the direct involvement of Rac-1 in the
STAT3 phosphorylation because STAT3 phosphorylation
was observed at 1 h when ROS generation was not induced
yet. As shown in Fig. 4B, overexpression of DN-RacT17N
inhibited the AGE-induced STAT3 phosphorylation, while
CA-RacG12V treatment augmented the AGE eﬀects. Under
the conditions of CA-RacG12V-overexpression, DPI did not
signiﬁcantly decrease the levels of STAT3 phosphorylation in
AGE-exposed Hep3B cells. These observations suggest that
Fig. 4. Eﬀects of AGEs and PEDF on STAT3 phosphorylations in Hep3B cells. (A) Hep3B cells were treated with 100 lg/ml AGE–BSA in the
presence or absence of 100 nM PEDF for the indicated time periods. (B) Hep3B cells were transfected with empty vector (control) or the indicated
amounts of DN-RacT17N or CA-RacG12V, and then treated with 100 lg/ml AGE–BSA in the presence or absence of 10 nM DPI for 1 h. Then,
STAT3 phosphorylation on Tyr-705 and Ser-727 was analyzed by western blots. Data were normalized by the intensity of total STAT3 signals. (A)
*P < 0.05. (B) *P < 0.05 compared to the value with empty vector. N = 3, Similar results were obtained in three independent experiments.
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STAT3 phosphorylation.3.6. Eﬀects of AGEs and PEDF on NF-jB p65 activity in Hep3B
cells
NF-jB is also known to be involved in transcriptional regu-
lation of CRP gene [27]. Therefore, we further examined
whether AGEs could induce NF-jB p65 activity in Hep3B
cells. As shown in Fig. 5A, NF-jB p65 activity in Hep3B cells
was signiﬁcantly induced by AGE treatment for 1 h. After 1-h
incubation, the activity was gradually decreased and returned
to the basal at 24 h. 100 nM PEDF was found to signiﬁcantly
suppress the AGE-induced increase in NF-jB p65 activity in
Hep3B cells (Fig. 5B). Furthermore, as the case of STAT3phosphorylation, overexpression of DN-RacT17N inhibited
the AGE-induced increase in NF-jB p65 activity, while CA-
RacG12V treatment augmented the AGE eﬀects. Under the
conditions of CA-RacG12V-overexpression, DPI did not sig-
niﬁcantly decrease the levels of NF-jB p65 activity in AGE-
exposed Hep3B cells. These observations suggest that ROS is
not involved in the Rac-1-mediated AGE-signaling to NF-jB
activation (Fig. 5C).4. Discussion
In the present study, we demonstrated for the ﬁrst time that
AGE–RAGE interaction stimulated hepatic CRP production
in vitro by inducing ROS generation and that PEDF blocked
Fig. 5. Eﬀects of AGEs or PEDF on NF-jB p65 activity in Hep3B
cells. Hep3B cells were treated with 100 lg/ml AGE–BSA or BSA in
the presence or absence of 100 nM PEDF for the indicated time period
(A) or 1 h (B). (C) Hep3B cells were transfected with empty vector
(control) or the indicated amounts of DN-RacT17N or CA-RacG12V,
and then treated with 100 lg/ml AGE–BSA in the presence or absence
of 10 nM DPI for 1 h. Then, NF-jB p65 activity was measured.
*P < 0.05 compared to the value without treatment (A) or 100 lg/ml
AGEs alone (B). (C) *P < 0.05 compared to the value with empty
vector. N = 3. Similar results were obtained in three independent
experiments.
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on the basis of the following evidence: (1) AGEs stimulated
CRP expression in Hep3B cells at both mRNA and protein
levels, which was dose-dependently suppressed by PEDF
(Fig. 1A and C); (2) AGEs increased intracellular ROS gener-ation in Hep3B cells, which was also inhibited by PEDF
(Fig. 2B); (3) antiserum against RAGE, an anti-oxidant,
NAC, a glutathione peroxidase mimics, ebselen, or an inhibi-
tor of NADPH oxidase, DPI blocked the AGE-induced upreg-
ulation of CRP mRNA levels as well as ROS generation in
Hep3B cells (Figs. 1B, C, 2A and B); (4) overexpression of
dominant negative Rac-1, an essential component of NADPH
oxidase, dose-dependently decreased the CRP mRNA levels in
AGE-exposed Hep3B cells, whereas that of constitutive active
Rac-1 augmented the AGE eﬀects (Fig. 3A); (5) PEDF inhib-
ited the AGE-elicited Rac-1 activation in Hep3B cells (Fig. 3B
and C). These observations suggest that AGEs could be one of
the potent inducers of CRP proteins by liver, thereby being in-
volved in the pathogenesis of accelerated atherosclerosis in dia-
betes and that PEDF may work as an anti-inﬂammatory agent
against AGEs in the liver.
In vitro-modiﬁed AGEs were prepared by incubating BSA
with glyceraldehyde for 1 week; this process produces rela-
tively highly-modiﬁed proteins in comparison to those
in vivo. However, it is unlikely that extensively-modiﬁed AGEs
that were formed under the in vitro-conditions may exert
non-speciﬁc eﬀects because we have previously found that
immunological epitope of glyceraldehyde-modiﬁed AGEs
was actually present in serum of diabetic patients and that
the concentration (10–100 lg/ml) of in vitro-prepared AGEs
used here were comparable with those of the in vivo diabetic
situation [28,29].
The data presented here are highly dependent on the purity
of PEDF proteins prepared. However, it is also unlikely that
the eﬀects of PEDF on Hep3B cells were non-speciﬁc for the
following reasons; (1) we have previously shown that puriﬁed
PEDF proteins revealed a single band in a SDS–PAGE analy-
sis [21]; (2) we demonstrated here that polyclonal Abs against
PEDF completely neutralized the biological eﬀects of PEDF
on Hep3B cells (Figs. 1A and 2B). Furthermore, we should dis-
cuss the possibilities that the concentrations of PEDF used
here were supraphysiologic levels and that PEDF exerted toxic
eﬀects on Hep3B cells. In this regard, we, along with others,
have recently found that human blood concentration of PEDF
was about 100–300 nM [30,31]. These observations suggest
that the concentrations of PEDF used in these experiments
were within a physiological range.
STAT3 participates in transcriptional activation of CRP
gene by IL-6 [25]. Further, phosphorylation of STAT3 on
Tyr-705 and Ser-727 is required for maximal transcriptional
activity [26]. We demonstrated here for the ﬁrst time that AGEs
induced STAT3 phosphorylations on both tyrosine (Tyr-705)
and serine (Ser-727) residues, which were blocked by PEDF
(Fig. 4A). In this study, STAT3 phosphorylation was observed
at 1h after AGE treatment when the ROS generation was not
induced yet. In addition, overexpression of DN-RacT17N
inhibited the AGE-induced STAT3 phosphorylation, whereas
that of CA-RacG12V augmented the AGE eﬀect (Fig. 4B).
Further, under the conditions of CA-RacG12V-overexpres-
sion, DPI did not signiﬁcantly decrease the levels of STAT3
phosphorylation in AGE-exposed Hep3B cells. Taken together,
these observations suggest that PEDF may inhibit the STAT3-
dependent transcriptional activation of CRP gene in Hep3G
cells by suppressing Rac-1 activation in a ROS-independent
manner.
We also found here that inhibition of NF-jB transcriptional
activity was another downstream target of PEDF. Since curcu-
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ulation of CRP mRNA levels (data not shown), PEDF could
also inhibit the CRP gene expression in AGE-exposed Hep3B
cells by suppressing NF-jB p65 activity. As the case of STAT3
phosphorylation, NF-jB p65 activation was observed at 1 h
when the ROS generation was not induced yet. Further,
Rac-1 involvement in the AGE-induced NF-jB p65 activation
was demonstrated in DN-RacT17N and CA-RacG12V experi-
ments (Fig. 5C). These observations suggest that PEDF may
also decrease CRP gene expression in AGE-exposed Hep3B
cells by suppressing the Rac-1-induced NF-jB activation. Un-
der the conditions of CA-RacG12V-overexpression, DPI did
not signiﬁcantly decrease the levels of NF-jB p65 activity in
AGE-exposed Hep3B cells, thus suggesting that ROS is not in-
volved in this pathway. Agrawal et al. have reported that CRP
gene in Hep3B cells is induced by IL-6 via transcriptional acti-
vation of STAT3, while IL-1, which alone has no eﬀect, poten-
tiates the eﬀects of IL-6 [2]. In their paper, they have shown that
IL-1 enhances the eﬀects of STAT3 on CRP gene induction via
NF-jB activation, thus suggesting that NF-jB activation is
responsible for the synergistic eﬀect of IL-1 on IL-6-induced
CRP expression in Hep3B cells [2]. Moreover, the promoter
of the CRP gene has been shown to include STAT3 and NF-
jB binding sites [2,27]. These ﬁndings further support our con-
cept that both transcriptional factors are directly involved in
CRP gene induction elicited by AGEs.
Taken together, the present observations suggest that there
exist at least two distinct signaling pathways to CRP gene
induction in AGE-exposed Hep3B cells. One is the Rac-1-in-
volved NADPH oxidase-mediated ROS-dependent pathway,
and the other is the Rac-1-induced STAT3- and NF-jB-depen-
dent one, which is not directly mediated by ROS (Fig. 6). It is
conceivable that the early stage of CRP induction by AGEs is
ROS-independent whereas the later stage of CRP induction re-
lies on a ROS-mediated pathway. Our present study suggestsFig. 6. Possible signaling pathways of the AGE-induced CRP expres-
sion in Hep3B cells.that PEDF could inhibit the AGE-induced CRP expression
by the liver via suppression of Rac-1 activation and may play
a protective role against atherosclerosis.
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